Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc.

NASDAQ:TNGX

Overview | Financials
Company Name Tango Therapeutics, Inc.
Symbol TNGX
Currency USD
Price 3.1
Market Cap 332,995,800
Dividend Yield 0%
52-week-range 2.7 - 13.005
Industry Biotechnology
Sector Healthcare
CEO Dr. Barbara L. Weber M.D.
Website https://www.tangotx.com

An error occurred while fetching data.

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease

Related Stocks

Aura Biosciences, Inc. logo

Aura Biosciences, Inc.

AURA

8.2 USD

Geron Corporation logo

Geron Corporation

GERN

3.49 USD

Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc.

STOK

11.68 USD

PetIQ, Inc. logo

PetIQ, Inc.

PETQ

30.98 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

1.1 USD

Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

CRBU

1.8 USD

GH Research PLC logo

GH Research PLC

GHRS

6.85 USD

ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

53.35 USD

Financials

Numbers are in millions USD

Numbers are in millions USD